Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GX-19N DNA Vaccine in Healthy Volunteers
NCT04715997Phase 2Completed
- Sponsor
- Genexine
- Start
- Dec 2020
- Primary completion
- Apr 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of GX-19N in coronavirus disease 2019 (COVID-19), sponsored by Genexine. Started Dec 2020; status: completed.
02
Drugs
GX-19N
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04715997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04715997.